Literature DB >> 27516242

Iron deficiency, anemia, and mortality in renal transplant recipients.

Michele F Eisenga1, Isidor Minović2,3, Stefan P Berger2, Jenny E Kootstra-Ros3, Else van den Berg2, Ineke J Riphagen2,3, Gerjan Navis2, Peter van der Meer4, Stephan J L Bakker2, Carlo A J M Gaillard2.   

Abstract

Anemia, iron deficiency anemia (IDA), and iron deficiency (ID) are highly prevalent in renal transplant recipients (RTR). Anemia is associated with poor outcome, but the role of ID is unknown. Therefore, we aimed to investigate the association of ID, irrespective of anemia, with all-cause mortality in RTR. Cox regression analyses were used to investigate prospective associations. In 700 RTR, prevalences of anemia, IDA, and ID were 34%, 13%, and 30%, respectively. During follow-up for 3.1 (2.7-3.9) years, 81 (12%) RTR died. In univariable analysis, anemia [HR, 1.72 (95%CI: 1.11-2.66), P = 0.02], IDA [2.44 (1.48-4.01), P < 0.001], and ID [2.04 (1.31-3.16), P = 0.001] were all associated with all-cause mortality. In multivariable analysis, the association of anemia with mortality became weaker after adjustment for ID [1.52 (0.97-2.39), P = 0.07] and disappeared after adjustment for proteinuria and eGFR [1.09 (0.67-1.78), P = 0.73]. The association of IDA with mortality attenuated after adjustment for potential confounders. In contrast, the association of ID with mortality remained independent of potential confounders, including anemia [1.77 (1.13-2.78), P = 0.01]. In conclusion, ID is highly prevalent among RTR and is associated with an increased risk of mortality, independent of anemia. As ID is a modifiable factor, correction of ID could be a target to improve survival.
© 2016 The Authors. Transplant International published by John Wiley & Sons Ltd on behalf of Steunstichting ESOT.

Entities:  

Keywords:  anemia; iron deficiency; kidney transplantation; mortality

Mesh:

Substances:

Year:  2016        PMID: 27516242     DOI: 10.1111/tri.12821

Source DB:  PubMed          Journal:  Transpl Int        ISSN: 0934-0874            Impact factor:   3.782


  13 in total

1.  C-Terminal Fibroblast Growth Factor 23, Iron Deficiency, and Mortality in Renal Transplant Recipients.

Authors:  Michele F Eisenga; Marco van Londen; David E Leaf; Ilja M Nolte; Gerjan Navis; Stephan J L Bakker; Martin H de Borst; Carlo A J M Gaillard
Journal:  J Am Soc Nephrol       Date:  2017-08-03       Impact factor: 10.121

2.  Serum Iron Protects from Renal Postischemic Injury.

Authors:  Céline Vaugier; Mariane T Amano; Jonathan M Chemouny; Michael Dussiot; Claire Berrou; Marie Matignon; Sanae Ben Mkaddem; Pamella H M Wang; Aurélie Fricot; Thiago T Maciel; Damien Grapton; Jacques R R Mathieu; Carole Beaumont; Marie-Noëlle Peraldi; Carole Peyssonnaux; Laurent Mesnard; Eric Daugas; François Vrtovsnik; Renato C Monteiro; Olivier Hermine; Yelena Z Ginzburg; Marc Benhamou; Niels O S Camara; Martin Flamant; Ivan C Moura
Journal:  J Am Soc Nephrol       Date:  2017-08-07       Impact factor: 10.121

3.  Type of proton-pump inhibitor and risk of iron deficiency in kidney transplant recipients - results from the TransplantLines Biobank and Cohort Study.

Authors:  Rianne M Douwes; Joanna Sophia J Vinke; António W Gomes-Neto; Gizem Ayerdem; Gaston van Hassel; Stefan P Berger; Daan J Touw; Hans Blokzijl; Stephan J L Bakker; Martin H de Borst; Michele F Eisenga
Journal:  Transpl Int       Date:  2021-10-07       Impact factor: 3.842

4.  The prevalence and associated mortality of non-anaemic iron deficiency in older adults: a 14 years observational cohort study.

Authors:  Keir E J Philip; Ahmed S Sadaka; Michael I Polkey; Nicholas S Hopkinson; Andrew Steptoe; Daisy Fancourt
Journal:  Br J Haematol       Date:  2020-02-18       Impact factor: 8.615

5.  Post renal transplant anemia: severity, causes and their association with graft and patient survival.

Authors:  Amir Schechter; Anat Gafter-Gvili; Daniel Shepshelovich; Ruth Rahamimov; Uzi Gafter; Eytan Mor; Avry Chagnac; Benaya Rozen-Zvi
Journal:  BMC Nephrol       Date:  2019-02-13       Impact factor: 2.388

6.  Chronic Use of Proton-Pump Inhibitors and Iron Status in Renal Transplant Recipients.

Authors:  Rianne M Douwes; António W Gomes-Neto; Michele F Eisenga; Joanna Sophia J Vinke; Martin H de Borst; Else van den Berg; Stefan P Berger; Daan J Touw; Eelko Hak; Hans Blokzijl; Gerjan Navis; Stephan J L Bakker
Journal:  J Clin Med       Date:  2019-09-03       Impact factor: 4.241

7.  Association between post-transplant red cell distribution width and prognosis of kidney transplant recipients.

Authors:  Sehoon Park; Young Hoon Kim; Yong Chul Kim; Mi-Yeon Yu; Jung Pyo Lee; Duck Jong Han; Yon Su Kim; Su-Kil Park
Journal:  Sci Rep       Date:  2017-10-23       Impact factor: 4.379

8.  Association of different iron deficiency cutoffs with adverse outcomes in chronic kidney disease.

Authors:  Michele F Eisenga; Ilja M Nolte; Peter van der Meer; Stephan J L Bakker; Carlo A J M Gaillard
Journal:  BMC Nephrol       Date:  2018-09-12       Impact factor: 2.388

9.  The association between use of proton-pump inhibitors and excess mortality after kidney transplantation: A cohort study.

Authors:  Rianne M Douwes; António W Gomes-Neto; Michele F Eisenga; Elisabet Van Loon; Joëlle C Schutten; Rijk O B Gans; Maarten Naesens; Else van den Berg; Ben Sprangers; Stefan P Berger; Gerjan Navis; Hans Blokzijl; Björn Meijers; Stephan J L Bakker; Dirk Kuypers
Journal:  PLoS Med       Date:  2020-06-15       Impact factor: 11.069

10.  Iron deficiency, with and without anaemia, across strata of kidney function in kidney transplant recipients.

Authors:  Gizem Ayerdem; Gaston van Hassel; Joanna Sophia J Vinke; Daan J Kremer; Carlo A J M Gaillard; Martin H de Borst; Stephan J L Bakker; Michele F Eisenga
Journal:  Nephrol Dial Transplant       Date:  2021-12-02       Impact factor: 5.992

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.